Cogentix Medical (NASDAQ: CGNT) and ABAXIS (NASDAQ:ABAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitabiliy, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Risk & Volatility

Cogentix Medical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, ABAXIS has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cogentix Medical and ABAXIS, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogentix Medical 0 0 1 0 3.00
ABAXIS 1 4 1 0 2.00

ABAXIS has a consensus price target of $47.88, indicating a potential downside of 7.58%. Given ABAXIS’s higher possible upside, analysts plainly believe ABAXIS is more favorable than Cogentix Medical.

Valuation & Earnings

This table compares Cogentix Medical and ABAXIS’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cogentix Medical $52.59 million 2.02 $2.88 million ($0.52) -3.38
ABAXIS $227.22 million 5.16 $51.83 million $1.43 36.22

ABAXIS has higher revenue and earnings than Cogentix Medical. Cogentix Medical is trading at a lower price-to-earnings ratio than ABAXIS, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.8% of Cogentix Medical shares are held by institutional investors. Comparatively, 98.3% of ABAXIS shares are held by institutional investors. 35.5% of Cogentix Medical shares are held by company insiders. Comparatively, 4.1% of ABAXIS shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


This table compares Cogentix Medical and ABAXIS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cogentix Medical -42.47% -22.70% -14.32%
ABAXIS 14.40% 11.37% 9.95%


ABAXIS pays an annual dividend of $0.56 per share and has a dividend yield of 1.1%. Cogentix Medical does not pay a dividend. ABAXIS pays out 39.2% of its earnings in the form of a dividend.


ABAXIS beats Cogentix Medical on 11 of the 14 factors compared between the two stocks.

Cogentix Medical Company Profile

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

ABAXIS Company Profile

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with's FREE daily email newsletter.